Koo,

I need to do more due diligence, but I'm pretty sure that the leptomeningeal carcinomatosis (LC) from breast cancer that Angiochem's ANG1005 is targeting is a very specific and uncommon version of breast-cancer derived brain cancer. This is not the same focus as the xB3-001 to get Herceptin (Trastuzumab) across the BBB and into the brain for HER2-positive breast cancer derived brain metastases. There may be some overlap in the patient populations, but I believe that the HER2-positive population is much larger than the LC population, that not all LC's are HER2-positive, and that not all HER2-positive brain metastases are LC.

BearDownAZ